Larvol Delta - Viracta-Therapeutics-Announces-First-Clinical-Response-in-EpsteinBarr-VirusPositive-EBV-Solid-Tumor-Setting-and-Outlines-Key-2023-Clinical-Objectives

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

nanatinostat (VRx-3996) - Viracta Therap

https://www.globenewswire.com/news-release/2023/01/08/2584738/0/en/Viracta-Therapeutics-Announces-First-Clinical-Response-in-Epstein-Barr-Virus-Positive-EBV-Solid-Tumor-Setting-and-Outlines-Key-2023-Clinical-Objectives.html

Jan 8, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next